Crinetics Pharmaceuticals (CRNX) Operating Income (2017 - 2026)

Crinetics Pharmaceuticals' Operating Income history runs 10 years deep, the most recent figure standing at -$140.4 million for Q1 2026.

• In Q1 2026, Operating Income fell 26.01% year-over-year to -$140.4 million; the TTM figure through Mar 2026 stood at -$545.7 million (down 44.86% YoY), while the FY2025 annual figure was -$516.8 million, down 52.5% from the prior year.
• Operating Income was -$140.4 million for Q1 2026 at Crinetics Pharmaceuticals, down from -$133.7 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$33.8 million in Q1 2022 to a low of -$142.6 million in Q3 2025.
• Historically, Operating Income has averaged -$81.6 million across 5 years, with a median of -$73.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Income tumbled 64.99% in 2022, then slipped 23.12% in 2023.
• A 5-year view of Operating Income shows it stood at -$47.6 million in 2022, then sank by 31.76% to -$62.7 million in 2023, then sank by 51.21% to -$94.7 million in 2024, then sank by 41.08% to -$133.7 million in 2025, then dropped by 5.02% to -$140.4 million in 2026.
• The last three Operating Income figures came in at -$140.4 million (Q1 2026), -$133.7 million (Q4 2025), and -$142.6 million (Q3 2025), per Business Quant data.